Frontlight ResearchEarly access
Taking peoplePhase 2
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
Key facts
- Who runs it
- Eli Lilly and Company
- Where
- Beverly Hills, Bowie, Brownsburg, Chicago, Covington, Hamden, Houston, Jacksonville, Las Vegas, Long Beach, Lynchburg, Mesquite, Miami, Miami Lakes, Montclair, New York, Newport News, Northridge, Pennington, Phoenix, Redmond, Roanoke, San Antonio, Seattle, Tucson, Winter Park, and Worcester, United StatesSee the 29 sitesAlso in 3 other countries, 12 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 60 people, planned
- Started
- 8 Dec 2025
- Expected to end
- Aug 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Solbinsiran
- Placebo
- Record updated
- 4 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- History of fasting triglyceride levels of ≥500 milligrams per deciliter (mg/dL), based on medical history
- Fasting triglyceride level ≥500 mg/dL at two separate visits during screening (at least 7 days apart)
- Have a body mass index (BMI) within the range of 18.5 to 45.0 kilograms per square meter (kg/m2) (inclusive)
Who cannot take part
- Have had a major atherosclerotic cardiovascular event within the past 3 months prior to screening
- Have a history of chronic alcohol abuse within 3 years prior to screening
- Have a known genetically confirmed diagnosis of Familial Chylomicronemia Syndrome
- Have a history of or planned treatment involving any gene editing or gene therapy modalities, including but not limited to CRISPR-based, viral vector-mediated, or other genetic modification techniques
Where in United States
Also in 3 other countries, 12 sites
- National Heart InstituteBeverly Hills, United StatesNo longer taking part
- Flourish Research - BowieBowie, United StatesNo longer taking part
- Investigators Research GroupBrownsburg, United StatesNo longer taking part
- Great Lakes Clinical Trials - RavenswoodChicago, United StatesNo longer taking part
- Saint Elizabeth Healthcare - Saint Elizabeth Covington HospitalCovington, United StatesNo longer taking part
- CMR of Greater New Haven, LLCHamden, United StatesNo longer taking part
- Cardiovascular Specialists of WillowbrookHouston, United StatesNo longer taking part
- Northeast Research Institute - Downtown OfficeJacksonville, United StatesNo longer taking part
- AB Clinical TrialsLas Vegas, United StatesNo longer taking part
- Ark Clinical ResearchLong Beach, United StatesNo longer taking part
- Stroobants Cardiovascular CenterLynchburg, United StatesNo longer taking part
- Southern Endocrinology AssociatesMesquite, United StatesNo longer taking part
- Novera Clinical ResearchMiami, United StatesNo longer taking part
- Inpatient Research ClinicMiami Lakes, United StatesNo longer taking part
- Catalina Research Institute, LLCMontclair, United StatesNo longer taking part
- Icahn School of Medicine at Mount SinaiNew York, United StatesNo longer taking part
- Weill Cornell Medical CollegeNew York, United StatesNo longer taking part
- TPMG (Tidewater Physicians Multispecialty Group) Clinical ResearchNewport News, United StatesNo longer taking part
- Valley Clinical Trials, LLC dba Flourish ResearchNorthridge, United StatesNo longer taking part
- Clinical Research of PhiladelphiaPennington, United StatesNo longer taking part
- Onyx Clinical ResearchPhoenix, United StatesNo longer taking part
- Eastside Research AssociatesRedmond, United StatesNo longer taking part
- Carilion ClinicRoanoke, United StatesNo longer taking part
- American Research Corporation at Texas Liver InstituteSan Antonio, United StatesNo longer taking part
- Endeavor Clinical TrialsSan Antonio, United StatesNo longer taking part
- UW Medicine Diabetes InstituteSeattle, United StatesNo longer taking part
- Synexus Clinical Research US, Inc./Orange Grove Family PracticeTucson, United StatesNo longer taking part
- Clinical Site Partners, LLC dba Flourish ResearchWinter Park, United StatesNo longer taking part
- University of Massachusetts Chan Medical SchoolWorcester, United StatesNo longer taking part
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections.
The 2 groups in the trial
- SolbinsiranTreatment being tested
Participants will receive solbinsiran subcutaneously (SC)
- PlaceboPlacebo, for comparison
Participants will receive placebo SC
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 (Solbinsiran) in Adults With Severe Hypertriglyceridemia
- Record updated
- 4 November 2026